BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 14688025)

  • 1. Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas.
    Fransén K; Klintenäs M; Osterström A; Dimberg J; Monstein HJ; Söderkvist P
    Carcinogenesis; 2004 Apr; 25(4):527-33. PubMed ID: 14688025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.
    Yuen ST; Davies H; Chan TL; Ho JW; Bignell GR; Cox C; Stephens P; Edkins S; Tsui WW; Chan AS; Futreal PA; Stratton MR; Wooster R; Leung SY
    Cancer Res; 2002 Nov; 62(22):6451-5. PubMed ID: 12438234
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRAF mutations in colorectal cancer are associated with distinct clinical characteristics and worse prognosis.
    Kalady MF; Dejulius KL; Sanchez JA; Jarrar A; Liu X; Manilich E; Skacel M; Church JM
    Dis Colon Rectum; 2012 Feb; 55(2):128-33. PubMed ID: 22228154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
    Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
    Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases.
    Baldus SE; Schaefer KL; Engers R; Hartleb D; Stoecklein NH; Gabbert HE
    Clin Cancer Res; 2010 Feb; 16(3):790-9. PubMed ID: 20103678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma.
    Krol LC; 't Hart NA; Methorst N; Knol AJ; Prinsen C; Boers JE
    Eur J Cancer; 2012 May; 48(7):1108-15. PubMed ID: 22446020
    [TBL] [Abstract][Full Text] [Related]  

  • 7. BRAF and KRAS mutations in colorectal hyperplastic polyps and serrated adenomas.
    Chan TL; Zhao W; Leung SY; Yuen ST;
    Cancer Res; 2003 Aug; 63(16):4878-81. PubMed ID: 12941809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Colorectal cancer with mutation in BRAF, KRAS, and wild-type with respect to both oncogenes showing different patterns of DNA methylation.
    Nagasaka T; Sasamoto H; Notohara K; Cullings HM; Takeda M; Kimura K; Kambara T; MacPhee DG; Young J; Leggett BA; Jass JR; Tanaka N; Matsubara N
    J Clin Oncol; 2004 Nov; 22(22):4584-94. PubMed ID: 15542810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression.
    Calistri D; Rengucci C; Seymour I; Lattuneddu A; Polifemo AM; Monti F; Saragoni L; Amadori D
    J Cell Physiol; 2005 Aug; 204(2):484-8. PubMed ID: 15702478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic BRAF-V600E mutations in familial colorectal cancer.
    Vandrovcova J; Lagerstedt-Robinsson K; Påhlman L; Lindblom A
    Cancer Epidemiol Biomarkers Prev; 2006 Nov; 15(11):2270-3. PubMed ID: 17119056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer.
    Oliveira C; Velho S; Domingo E; Preto A; Hofstra RM; Hamelin R; Yamamoto H; Seruca R; Schwartz S
    Oncogene; 2005 Nov; 24(51):7630-4. PubMed ID: 16007118
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mutational activation of the RAS-RAF-MAPK and the Wnt pathway in small intestinal adenocarcinomas.
    Bläker H; Helmchen B; Bönisch A; Aulmann S; Penzel R; Otto HF; Rieker RJ
    Scand J Gastroenterol; 2004 Aug; 39(8):748-53. PubMed ID: 15513360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. No evidence for mutation of B-RAF in urothelial carcinomas of the bladder and upper urinary tract.
    Stoehr R; Brinkmann A; Filbeck T; Gamper C; Wild P; Blaszyk H; Hofstaedter F; Knuechel R; Hartmann A
    Oncol Rep; 2004 Jan; 11(1):137-41. PubMed ID: 14654916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRAF mutations in metastatic melanoma: a possible association with clinical outcome.
    Kumar R; Angelini S; Czene K; Sauroja I; Hahka-Kemppinen M; Pyrhönen S; Hemminki K
    Clin Cancer Res; 2003 Aug; 9(9):3362-8. PubMed ID: 12960123
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma.
    Kang S; Kim HS; Seo SS; Park SY; Sidransky D; Dong SM
    Gynecol Oncol; 2007 Jun; 105(3):662-6. PubMed ID: 17360030
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRAF mutation detection and identification by cycling temperature capillary electrophoresis.
    Hinselwood DC; Abrahamsen TW; Ekstrøm PO
    Electrophoresis; 2005 Jun; 26(13):2553-61. PubMed ID: 15948220
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of mutations in APC, CTNNB1, and BRAF in Tunisian patients with sporadic colorectal cancer.
    Bougatef K; Ouerhani S; Moussa A; Kourda N; Coulet F; Colas C; Lahely YB; Najjar T; Ben Jilani S; Benammar-Elgaaied A; Soubrier F; Marrakchi R
    Cancer Genet Cytogenet; 2008 Nov; 187(1):12-8. PubMed ID: 18992635
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased cancer predisposition in family members of colorectal cancer patients harboring the p.V600E BRAF mutation: a population-based study.
    Wish TA; Hyde AJ; Parfrey PS; Green JS; Younghusband HB; Simms MI; Fontaine DG; Dicks EL; Stuckless SN; Gallinger S; McLaughlin JR; Woods MO; Green RC
    Cancer Epidemiol Biomarkers Prev; 2010 Jul; 19(7):1831-9. PubMed ID: 20570909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High sensitivity scanning of colorectal tumors and matched plasma DNA for mutations in APC, TP53, K-RAS, and BRAF genes with a novel DHPLC fluorescence detection platform.
    Lilleberg SL; Durocher J; Sanders C; Walters K; Culver K
    Ann N Y Acad Sci; 2004 Jun; 1022():250-6. PubMed ID: 15251969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitogen-activated protein kinase signaling is activated in prostate tumors but not mediated by B-RAF mutations.
    Burger M; Denzinger S; Hammerschmied C; Tannapfel A; Maderstorfer A; Wieland WF; Hartmann A; Stoehr R
    Eur Urol; 2006 Nov; 50(5):1102-9; discussion 1109-10. PubMed ID: 16413100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.